Table 1.

Description of Study Population

		Overall	TP53-mutated		KRAS-mutated		CpG Island Methylator Phenotype High		Microsatellite Instability		BRAF-mutated
		(N = 1893)	(N = 864)	0.01	(N = 569)	%	(N = 354)	(%)	(N = 170)	(%)	(N = 90)	(%)
Study Center	Kaiser Permanente	1144	507	0.44	336	0.29	222	0.19	107	0.09	58	0.05
	Utah	749	357	0.48	233	0.31	132	0.18	47	0.06	32	0.04
Tumor Site	Colon	1150	500	0.43	347	0.30	275	0.24	154	0.13	90	0.08
	Rectal	743	364	0.49	222	0.30	79	0.11	16	0.02	NE2
Age (mean)		64.2	63.8		64.0		66.2		66.8		67.6
Sex (% F)		45.8	44.0		45.5		54.5		63.0		54.4
AJCC Stage	1	559	274	0.49	139	0.25	85	0.15	34	0.06	15	0.03
	2	489	195	0.40	160	0.33	93	0.19	59	0.12	23	0.05
	3	548	258	0.47	168	0.31	123	0.22	50	0.09	35	0.06
	4	266	123	0.46	89	0.33	50	0.19	10	0.04	16	0.06
5 Year Survival	Alive	1081	487	0.45	307	0.28	194	0.18	107	0.10	49	0.05
	Dead Colorectal Cancer	550	253	0.46	194	0.35	117	0.21	23	0.04	33	0.06
	Dead Other	198	93	0.47	57	0.29	34	0.17	20	0.10	7	0.04
	Lost to Follow-up	62	31	0.50	10	0.16	9	0.15	4	0.06	1	0.02

¹% refers to percentage of row

²NE indicates not evaluated